Get the Stockscreener App
33.36
0.49%
0.17
Ionis Pharmaceuticals Inc stock is traded at $33.36, with a volume of 455.38K.
It is up +0.49% in the last 24 hours and up +3.80% over the past month.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
See More
Previous Close:
$33.19
Open:
$33.255
24h Volume:
455.38K
Relative Volume:
0.29
Market Cap:
$5.28B
Revenue:
$803.07M
Net Income/Loss:
$-358.81M
P/E Ratio:
-13.67
EPS:
-2.44
Net Cash Flow:
$-374.21M
1W Performance:
+4.59%
1M Performance:
+3.80%
6M Performance:
-29.50%
1Y Performance:
-26.63%
1-Day Range:
$32.87
$33.54
1-Week Range:
$30.99
$33.54
52-Week Range:
$30.23
$52.34
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Name
Ionis Pharmaceuticals Inc
Sector
Industry
Phone
(760) 931-9200
Address
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
33.37 | 5.28B | 803.07M | -358.81M | -374.21M | -2.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.18 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
690.05 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
636.58 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
113.23 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-02-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-16-24 | Resumed | Jefferies | Buy |
| Jun-14-24 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Apr-10-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-02-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-23-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Sep-29-23 | Initiated | Raymond James | Strong Buy |
| Jul-31-23 | Upgrade | Citigroup | Neutral → Buy |
| Jun-07-23 | Resumed | Piper Sandler | Overweight |
| May-04-23 | Upgrade | Citigroup | Sell → Neutral |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Dec-21-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-09-22 | Resumed | Morgan Stanley | Overweight |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-31-22 | Resumed | Piper Sandler | Overweight |
| Mar-01-22 | Initiated | Citigroup | Sell |
| Mar-01-22 | Initiated | Guggenheim | Buy |
| Feb-01-22 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-14-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| May-07-21 | Upgrade | UBS | Sell → Neutral |
| Mar-01-21 | Upgrade | Barclays | Underweight → Equal Weight |
| Dec-16-20 | Initiated | UBS | Sell |
| Dec-15-20 | Upgrade | Cowen | Market Perform → Outperform |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Sep-02-20 | Initiated | The Benchmark Company | Hold |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Nov-07-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-10-19 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Aug-08-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Reiterated | Stifel | Hold |
| May-08-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-06-17 | Resumed | Goldman | Sell |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Aug-09-17 | Reiterated | Stifel | Hold |
| Mar-10-17 | Downgrade | Goldman | Neutral → Sell |
| Dec-28-16 | Reiterated | BMO Capital Markets | Outperform |
| Dec-27-16 | Reiterated | Leerink Partners | Mkt Perform |
View All
Ionis Pharmaceuticals Inc Stock (IONS) Latest News
ARK Investment Management LLC Sells 359,009 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives $60.00 Consensus Target Price from Analysts - MarketBeat
Investor Network: Ionis Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Ionis' Q4 Earnings and Sales Beat Estimates, Tryngolza Launch in Focus - MSN
FY2026 Earnings Estimate for IONS Issued By Leerink Partnrs - MarketBeat
Intellia: Balancing in vivo risk with validated targets - BioCentury
Ionis Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
C WorldWide Group Holding A S Has $13.98 Million Stock Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Leerink upgrades Ionis to outperform, cites Angelman drug - MSN
Ionis to present at upcoming investor conferences - Post Register
5 Undervalued Stocks That Crushed Q4 Earnings - Morningstar
Ionis Pharmaceuticals’ SWOT analysis: RNA pioneer’s stock faces pivotal year - Investing.com
Ionis Pharmaceuticals EVP Patrick O'Neil sells $39,046 in stock By Investing.com - Investing.com Canada
Ionis Pharmaceuticals Officer Sells Shares - TradingView
The Zacks Analyst Blog Highlights Merck, Sanofi, Regeneron and Ionis - Nasdaq
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Cut to $45.00 by Analysts at BMO Capital Markets - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) Issues Earnings Results - MarketBeat
Ionis Pharmaceuticals Reports Strong 2024 Results - TipRanks
Ionis Pharmaceuticals targets multibillion-dollar revenue potential with TRYNGOLZA and new launches - MSN
Ionis Pharmaceuticals price target lowered to $60 from $61 at Raymond James - Yahoo Finance
New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control - BioSpace
Ionis Earnings: Tryngolza Commercial Launch Underway; Shares Very Undervalued - Morningstar
Ionis posts Q4 beat as revenue base widens - MSN
Ionis Pharmaceuticals price target lowered to $38 from $45 at Stifel - MSN
What Analysts Are Saying About Ionis Pharmaceuticals Stock - Benzinga
Ionis presents new data on HAE drug donidalorsen By Investing.com - Investing.com Nigeria
BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment - GlobeNewswire Inc.
Why Ionis Pharmaceuticals (IONS) Is Among the Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
Ionis Continues to Expand Its Cardiology and Neurology Portfolio, Supporting Narrow Moat - Morningstar
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q4 2024 Earnings Call Transcript - Insider Monkey
Ionis stock target cut to $60 by Raymond James - Investing.com India
Ionis presents new data on HAE drug donidalorsen - Investing.com
Ionis Pharmaceuticals Full Year 2024 Earnings: Beats Expectations - Simply Wall St
Can This New HAE Treatment Transform Patient Care? Key Clinical Data Revealed - StockTitan
Ionis Pharmaceuticals Inc (IONS) Q4 2024 Earnings Call Highlights: Surpassing Revenue ... - Yahoo Finance
Ionis Pharmaceuticals: Q4 Earnings Snapshot - The Advocate
Ionis Pharmaceuticals (IONS) Reports Q4 Earnings: What Key Metrics Have to Say - MSN
Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates - MSN
12 Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
Ionis Pharmaceuticals: Positive Sentiment in Earnings Call - TipRanks
Ionis Pharmaceuticals (NASDAQ:IONS) Stock Quotes, Forecast and News Summary - Benzinga
Stifel cuts Ionis Pharmaceuticals target to $38, maintains Hold - Investing.com India
Ionis Pharmaceuticals Reports Strong Q4 Earnings After Recent FDA Approval (IONS) - Seeking Alpha
Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, Forecasts Over $600 Million In 2025 Sales - AOL
Ionis Pharma Beats Expectations for Q4 - MSN
Earnings call transcript: Ionis Pharmaceuticals Q4 2024 surpasses forecasts - Investing.com
Earnings call transcript: Ionis Pharmaceuticals Q4 2024 surpasses forecasts By Investing.com - Investing.com Nigeria
Ionis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits - Quantisnow
Ionis Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Ionis stock gains on Q4 beat (IONS:NASDAQ) - Seeking Alpha
Ionis Pharmaceuticals Inc Stock (IONS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ionis Pharmaceuticals Inc Stock (IONS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| O'NEIL PATRICK R. | EVP CLO & General Counsel |
Feb 04 '25 |
Sale |
31.62 |
6,165 |
194,939 |
57,452 |
| Monia Brett P | Chief Executive Officer |
Feb 04 '25 |
Sale |
31.65 |
38,843 |
1,229,463 |
180,683 |
2.93%
1.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):